🇺🇸 FDA
Patent

US 10759838

Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use

granted A61KA61K38/13A61K38/1709

Quick answer

US patent 10759838 (Myelin oligodendrocyte glycoprotein, myelin basic protein, and proteolipid protein compositions and methods of use) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Sep 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 27 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K38/13, A61K38/1709, A61P, A61P25/28